# US 2025/0320494 A1 · Inhibitors of expression and/or function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0320494 A1
- Document ID: US20250320494A1
- Status: Published application
- Kind: A1
- Application number: 18/869,034
- Filed: 2023-06-01
- Published: 2025-10-16
- Earliest claimed: 2022-06-01
- Assignees: E-Therapeutics PLC
- Applicants: E-Therapeutics PLC
- Inventors: Alan Victor WHITMORE; Julie BORGEL; Amy MCCARTHY; Graham CRAGGS; James LONGDEN; Ines DE SANTIAGO; Duncan BROWN; Ahmad Ali MORTAZAVI; Viviana MANNELLA; Muthusamy JAYARAMAN; Alexandre DEBACKER; Adrian MOGG
- Web page: https://patentgrep.com/patent/US20250320494A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/322: 2'-R Modification
- C12N 2310/351: Conjugate
- C12N 2310/3521: Methyl
- C12N 2310/3533: Halogen
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a disease related to a disorder of haemostasis, such as haemophilia.

## Claims

### Claim 1

An inhibitor of expression and/or function of ZPI for use in prevention or treatment of a disease related to a disorder of haemostasis, such as haemophilia.

### Claim 2 (depends on 1)

The inhibitor of expression and/or function of ZPI of claim 1, wherein said inhibitor is conjugated to one or more ligand moieties.

### Claim 3 (depends on 1, 2)

The inhibitor of expression and/or function of ZPI of claim 1 or 2, wherein said inhibitor is an siRNA oligomer.

### Claim 4

An inhibitor of expression and/or function of ZPI, wherein said inhibitor is conjugated to one or more ligand moieties.

### Claim 5 (depends on 4)

An inhibitor according to claim 4, wherein said inhibitor is an siRNA oligomer.

### Claim 6

An inhibitor of expression and/or function of ZPI, wherein said inhibitor is an siRNA oligomer.

### Claim 7 (depends on 6)

An inhibitor according to claim 6, wherein said inhibitor comprises an siRNA oligomer conjugated to one or more ligand moieties.

### Claim 8 (depends on 2, 4, 5, 7)

An inhibitor, or an inhibitor for use, according to claim 2, 4, 5 or 7, wherein said one or more ligand moieties comprise one or more GalNAc ligands or comprise one more GalNAc ligand derivatives.

### Claim 9 (depends on 2, 4, 5, 7)

An inhibitor, or an inhibitor for use, according to claim 2, 4, 5 or 7 wherein said one or more ligand moieties comprise one or more GalNAc ligand derivatives.

### Claim 10

An inhibitor, or an inhibitor for use, according to one or more preceding claims, wherein the target of the inhibitor is ZPI.

### Claim 11

An inhibitor, or inhibitor for use, according to one or more preceding claims, which is an siRNA oligomer having a first and a second strand wherein:
i) the first strand of the siRNA has a length in the range of 15 to 30 nucleosides, preferably 19 to 25 nucleosides, more preferably 23 or 25; even more preferably 23; and/or
ii) the second strand of the siRNA has a length in the range of 15 to 30 nucleosides, preferably 19 to 25 nucleosides, more preferably 21 nucleosides.

### Claim 12 (depends on 11)

An inhibitor, or inhibitor for use, according to claim 11, wherein the second sense strand further comprises one or more abasic nucleosides in a terminal region of the second strand, and wherein said abasic nucleoside(s) is/are connected to an adjacent nucleoside through a reversed internucleoside linkage.

### Claim 13 (depends on 12)

An inhibitor, or inhibitor for use, according to claim 12, wherein the second strand comprises:
i 2, or more than 2, abasic nucleosides in a terminal region of the second strand; and/or
ii 2, or more than 2, abasic nucleosides in either the 5′ or 3′ terminal region of the second strand; and/or
iii 2, or more than 2, abasic nucleosides in either the 5′ or 3′ terminal region of the second strand, wherein the abasic nucleosides are present in an overhang as herein described; and/or
iv 2, or more than 2, consecutive abasic nucleosides in a terminal region of the second strand, wherein preferably one such abasic nucleoside is a terminal nucleoside; and/or
v 2, or more than 2, consecutive abasic nucleosides in either the 5′ or 3′ terminal region of the second strand, wherein preferably one such abasic nucleoside is a terminal nucleoside in either the 5′ or 3′ terminal region of the second strand; and/or
vi a reversed internucleoside linkage connects at least one abasic nucleoside to an adjacent basic nucleoside in a terminal region of the second strand; and/or
vii a reversed internucleoside linkage connects at least one abasic nucleoside to an adjacent basic nucleoside in either the 5′ or 3′ terminal region of the second strand; and/or
viii an abasic nucleoside as the penultimate nucleoside which is connected via the reversed linkage to the nucleoside which is not the terminal nucleoside (called the antepenultimate nucleoside herein); and/or
ix abasic nucleosides as the 2 terminal nucleosides connected via a 5′-3′ linkage when reading the strand in the direction towards that terminus;
x abasic nucleosides as the 2 terminal nucleosides connected via a 3′-5′ linkage when reading the strand in the direction towards the terminus comprising the terminal nucleosides;
xi abasic nucleosides as the terminal 2 positions, wherein the penultimate nucleoside is connected via the reversed linkage to the antepenultimate nucleoside, and wherein the reversed linkage is a 5-5′ reversed linkage or a 3′-3′ reversed linkage;
xii abasic nucleosides as the terminal 2 positions, wherein the penultimate nucleoside is connected via the reversed linkage to the antepenultimate nucleoside, and wherein either
(1) the reversed linkage is a 5-5′ reversed linkage and the linkage between the terminal and penultimate abasic nucleosides is 3′5′ when reading towards the terminus comprising the terminal and penultimate abasic nucleosides; or
(2) the reversed linkage is a 3-3′ reversed linkage and the linkage between the terminal and penultimate abasic nucleosides is 5′3′ when reading towards the terminus comprising the terminal and penultimate abasic nucleosides.

### Claim 14 (depends on 12, 13)

An inhibitor, or inhibitor for use, according claim 12 or 13, wherein the reversed internucleoside linkage is at a terminal region which is distal to the 5′ terminal region of the second strand, or at a terminal region which is distal to the 3′ terminal region of the second strand.

### Claim 15 (depends on 12, 13, 14)

An inhibitor, or inhibitor for use, according to any one of claims 12 to 14, wherein the reversed internucleoside linkage is a 3′3 reversed linkage.

### Claim 16 (depends on 12, 13, 14)

An inhibitor, or inhibitor for use, according to any one of claims 12 to 14, wherein the reversed internucleoside linkage is a 5′5 reversed linkage.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

An inhibitor, or inhibitor for use, according to any one of claims 1 to 16, wherein one or more nucleosides on the first strand and/or the second strand is/are modified, to form modified nucleosides.

### Claim 18 (depends on 17)

An inhibitor, or inhibitor for use, according to claim 17, wherein the modification is a modification at the 2′-OH group of the ribose sugar, optionally selected from 2′-Me or 2′-F modifications.

### Claim 19 (depends on 17, 18)

An inhibitor, or inhibitor for use, according to claim 17 or 18, wherein the first strand comprises a 2′-F at any of position 14, position 2, position 6, or any combination thereof, counting from position 1 of said first strand.

### Claim 20 (depends on 17, 18)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 18, wherein the second strand comprises a 2′-F modification at position 7 and/or 9, and/or 11 and/or 13, counting from position 1 of said second strand.

### Claim 21 (depends on 17, 18, 19, 20)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 20, wherein the first and second strand each comprise 2′-Me and 2′-F modifications.

### Claim 22 (depends on 17, 18, 19, 20, 21)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 21, which is an siRNA, wherein the siRNA comprises at least one thermally destabilizing modification, suitably at one or more of positions 1 to 9 of the first strand counting from position 1 of the first strand, and/or at one or more of positions on the second strand aligned with positions 1 to 9 of the first strand, wherein the destabilizing modification is selected from a modified unlocked nucleic acid (UNA) and a glycol nucleic acid (GNA), preferably a glycol nucleic acid.

### Claim 23 (depends on 22)

An inhibitor, or inhibitor for use, according to claim 22, wherein the siRNA comprises at least one thermally destabilizing modification at position 7 of the first strand, counting from position 1 of the first strand.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22, 23)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 23, which is an siRNA, wherein the siRNA comprises 3 or more 2′-F modifications at positions 7 to 13 of the second strand, such as 4, 5, 6 or 7 2′-F modifications at positions 7 to 13 of the second strand, counting from position 1 of said second strand

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 24, which is an siRNA, wherein said second strand comprises at least 3, such as 4, 5 or 6, 2′-Me modifications at positions 1 to 6 of the second strand, counting from position 1 of said second strand.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 25, which is an siRNA, wherein said first strand comprises at least 5 2′-Me consecutive modifications at the 3′ terminal region, preferably including the terminal nucleoside at the 3′ terminal region, or at least within 1 or 2 nucleosides from the terminal nucleoside at the 3′ terminal region.

### Claim 27 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 26, which is an siRNA wherein said first strand comprises 7 2′-Me consecutive modifications at the 3′ terminal region, preferably including the terminal nucleoside at the 3′ terminal region.

### Claim 28 (depends on 17, 18, 19, 20, 21, 22, 23)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 23, which is an siRNA, wherein said modified nucleosides of said second strand comprise a modification pattern according to any one of the following (5′-3′):
(Me)8-(F)3-(Me)10.

### Claim 29 (depends on 17, 18, 19, 20, 21, 22, 23, 28)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 23 or 28, which is an siRNA, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern wherein said modifications are selected at least from 2′Me and 2′F sugar modifications, provided that the overall number of 2′F sugar modifications in the first strand does not consist of four, or six, 2′F modifications.

### Claim 30 (depends on 17, 18, 19, 20, 21, 22, 23, 28, 29)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 23 or 28 to 29, which is an siRNA, wherein said modifications are selected at least from 2′Me and 2′F sugar modifications, wherein the overall number of 2′F sugar modifications in the first strand consists of three, five or seven 2′F modifications.

### Claim 31 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

An inhibitor, or inhibitor for use, according to any one of claims 17 to 30, wherein the siRNA oligomer further comprises one or more phosphorothioate internucleoside linkages.

### Claim 32 (depends on 12, 31)

An inhibitor, or inhibitor for use, according to claim 31, wherein said one or more phosphorothioate internucleoside linkages are respectively between at least three consecutive positions in a 5′ or 3′ near terminal region of the second strand, whereby said near terminal region is preferably adjacent said terminal region wherein said one or more abasic nucleosides of said second strand is/are located according to at least claim 12.

### Claim 33 (depends on 31, 32)

An inhibitor, or inhibitor for use, according to claim 31 or 32, wherein said one or more phosphorothioate internucleoside linkages are respectively between at least three consecutive positions in a 5′ and/or 3′ terminal region of the first strand, whereby preferably a terminal position at the 5′ and/or 3′ terminal region of said first strand is attached to its adjacent position by a phosphorothioate internucleoside linkage.

### Claim 34 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

An inhibitor, or inhibitor for use according to any one of claims 11 to 33, wherein the oligomer is an siRNA and the second strand of the siRNA is conjugated directly or indirectly to one or more ligand moiety(s), wherein said ligand moiety is typically present at a terminal region of the second strand, preferably at the 3′ terminal region thereof.

### Claim 35 (depends on 34)

An inhibitor, or inhibitor for use according to claim 34, wherein the ligand moiety comprises
i) one or more GalNAc ligands; and/or
ii) one or more GalNAc ligand derivatives; and/or
iii) one or more GalNAc ligands and/or GalNAc ligand derivatives conjugated to said SiRNA through a linker.

### Claim 36 (depends on 35)

An inhibitor, or inhibitor for use according to claim 35, wherein said one or more GalNAc ligands and/or GalNAc ligand derivatives are conjugated directly or indirectly to the 5′ or 3′ terminal region of the second strand of the siRNA oligomer, preferably at the 3′ terminal region thereof.

### Claim 37 (depends on 35, 36)

An inhibitor, or inhibitor for use according to claim 35 or 36, wherein the ligand moiety comprises

### Claim 38 (depends on 35, 36)

An inhibitor, or inhibitor for use according to claim 35 or 36, having the structure:
wherein:
R1 at each occurrence is independently selected from the group consisting of hydrogen, methyl and ethyl;
R2 is selected from the group consisting of hydrogen, hydroxy, —OC1-3alkyl, —C(═O)OC1-3alkyl, halo and nitro;
X1 and X2 at each occurrence are independently selected from the group consisting of methylene, oxygen and sulfur;
m is an integer of from 1 to 6;
n is an integer of from 1 to 10;
q, r, s, t, v are independently integers from 0 to 4, with the proviso that:
(i) q and r cannot both be 0 at the same time; and
(ii) s, t and v cannot all be 0 at the same time;
Z is an oligomer

### Claim 39 (depends on 35, 36)

An inhibitor, or inhibitor for use according to claim 35 or 36, having the structure
wherein:
r and s are independently an integer selected from 1 to 16; and
Z is an oligomer.

### Claim 40

An inhibitor, or inhibitor for use according to one or more preceding claims, formulated as a pharmaceutical composition with an excipient and/or carrier.

### Claim 41

A pharmaceutical composition comprising an inhibitor according to one or more preceding claims, in combination with a pharmaceutically acceptable excipient or carrier.

### Claim 42

A pharmaceutical composition comprising an inhibitor according to one or more preceding claims, in combination with a pharmaceutically acceptable excipient or carrier, for use in the treatment of a disease related to a disorder of haemostasis, such as haemophilia.

### Claim 43

Use of ZPI as a target for identifying one or more therapeutic agents for the treatment of a disease related to a disorder of haemostasis, such as haemophilia.

### Claim 44

A method of treating or preventing a disease related to a disorder of haemostasis, such as haemophilia, which comprises administering to a patient an inhibitor of ZPI, such as an inhibitor as defined according to one or more preceding claims.

### Claim 45

ZPI for use as a biomarker of a disease related to a disorder of haemostasis, such as haemophilia.

### Claim 46

ZPI for use in an in vivo method of predicting susceptibility to a disease related to a disorder of haemostasis, such as haemophilia, typically by monitoring the sequence and/or level of expression and/or function of ZPI in a sample obtained from a patient.

### Claim 47

A method of predicting susceptibility to a disease related to a disorder of haemostasis, such as haemophilia, and optionally treating a disease related to a disorder of haemostasis, such as haemophilia, in a patient, said method comprising:
(a) obtaining a sample from the patient,
(b) detecting the sequence and/or expression and/or function of ZPI in said sample obtained from the patient,
(c) predicting susceptibility to a disease related to a disorder of haemostasis, such as haemophilia, based on the sequence and/or expression and/or function of ZPI in said sample obtained from the patient,
(d) preferably administering to the diagnosed patient an effective amount of an inhibitor of ZPI.

### Claim 48

An inhibitor or composition according to any preceding claim, in the preparation of a medicament for use in the treatment of a disease related to a disorder of haemostasis, such as haemophilia.
